Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
NCT ID: NCT00954122
Last Updated: 2013-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
35 participants
INTERVENTIONAL
2009-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
NCT00779506
Seroquel XR in Adults With Schizophrenia
NCT00852631
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
NCT00882518
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
NCT00640601
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
NCT00090324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quetiapine XR
Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
Quetiapine XR (Seroquel XR)
Tablet, oral, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine XR (Seroquel XR)
Tablet, oral, once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PANSS total score of ³ 75
* CGI \> 4
* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
* Substance or alcohol dependence at enrollment
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmad Hatim Sulaiman,, M Psyc
Role: PRINCIPAL_INVESTIGATOR
University of Malaya
Badiah Yahya, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Permai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Johor Bahru, Johor Bahru, Malaysia
Research Site
Kuala Lumpur, , Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1443L00074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.